Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Fungal and Parasitic Infections

Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes

Cinzia Retini, Anna Vecchiarelli, Claudia Monari, Francesco Bistoni, Thomas R. Kozel
Cinzia Retini
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Vecchiarelli
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Monari
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Bistoni
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Kozel
Department of Microbiology, University of Nevada School of Medicine, Reno, Nevada 89557-00462
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.66.2.664-669.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

This report examines the effect of the major capsular polysaccharide of Cryptococcus neoformans, glucuronoxylomannan (GXM), on the antigen-presenting capability of human monocytes treated with acapsular cells of C. neoformans. We found that pretreatment of acapsular cryptococci with GXM downregulates, in a dose-dependent manner, the antigen-presenting capacity of monocytes, leading to reduced proliferative T-lymphocyte responses. Similar levels of suppression occurred when monocytes were exposed to encapsulated cryptococci or acapsular cryptococci that were pretreated with GXM. The magnitude of the T-cell response correlated with the ability of monocytes to ingest the yeast. Supernatant fluids from cocultures of monocytes and T cells cultured with encapsulated cryptococci contained higher levels of interleukin-10 (IL-10) than supernatant fluids of cells with acapsular cryptococci. Addition of anti-IL-10 monoclonal antibodies to the incubation medium of monocytes and T cells cultured with encapsulated cryptococci restored proliferative T-cell responses to levels observed during culture with acapsular cryptococci. Finally, treatment of monocytes with encapsulated cryptococci or GXM-treated acapsular cryptococci suppressed expression of class II major histocompatibility complex (MHC) molecules in a manner consistent with previous reports of IL-10-mediated suppression of class II MHC molecules and suppression of proliferative T-cell responses. These results suggest a link between GXM encapsulation, increased IL-10 synthesis by monocytes, decreased expression of class II MHC molecules on monocytes, and reduced proliferative T-cell responses.

Cryptococcus neoformansis an opportunistic fungus that produces a life-threatening meningoencephalitis in AIDS patients (10, 11, 25, 38). This fungus is believed to enter the body via inhalation of airborne yeast cells or conidia from the environment. During initial exposure to the microorganism, the capsule may be absent or small, but it is rapidly synthesized in vivo. The capsule represents a major virulence factor endowed with antiphagocytic and toleragenic properties (16, 17, 23, 31). Glucuronoxylomannan (GXM) is the major component of the capsule of C. neoformans, and studies focusing on capsular material have identified many regulatory effects on phagocytic cells (16, 19, 21, 24, 28, 39, 45). The large amount of this inhibitory substance found in the body fluids of patients with cryptococcosis (8, 36) raises the possibility that GXM exerts regulatory effects during a cryptococcal infection. Several reports indicate that GXM or products of C. neoformans that are rich in GXM induce or regulate the cell-mediated response toC. neoformans. Murphy and Cox found that intravenous injection of sera with high GXM titers from C. neoformans-infected mice into recipient mice suppresses the ability of the recipient mice to produce a normal delayed hypersensitivity response to cryptococcal antigens (30). Several studies from the Murphy laboratory found that intravenous injection of cryptococcal polysaccharides induces a cascade of suppressor cells and soluble factors that downregulate the anticryptococcal delayed hypersensitivity response (13, 29, 32-34). More recently, Blackstock reported that GXM stimulates an antigen-presenting cell (APC) to induce secretion by T cells of a T-suppressor factor that is specific for GXM (1).

Collins and Bancroft were the first to report that encapsulation ofC. neoformans greatly reduces the ability of C. neoformans-treated monocytes/macrophages to induce a T lymphoproliferative response (5). This report was followed by one presenting similar observations by Mody and Syme (26), as well as ours (43). Recently we found that GXM is a potent downregulator of proinflammatory cytokine release by human monocytes (45). This inhibitory effect is due, in part, to an increased secretion of interleukin-10 (IL-10) that appears, in turn, to be responsible for reduced secretion of tumor necrosis factor alpha (TNF-α), and/or IL-1β (6, 22, 46). A role for GXM encapsulation in suppression of the T lymphoproliferative response is supported by our observation that opsonization of encapsulated cryptococci with anti-GXM monoclonal antibodies (MAbs) enhances the ability of monocytes to process C. neoformans yeast cells, leading to an enhanced T proliferative response (44).

The objectives of our study were (i) to provide further evidence for the central role that encapsulation with GXM plays in reducing the ability of monocytes to process C. neoformans yeast cells, leading to a proliferative response by T lymphocytes, (ii) to determine the effect of GXM encapsulation on expression of major histocompatibility complex (MHC) class II molecules by monocytes, and (iii) to assess the importance of autologous IL-10 in altered expression of MHC class II molecules by monocytes and suppressed T lymphoproliferation. Our results confirmed the role of GXM in suppression of the T lymphoproliferative response and provide a link between the capability of GXM encapsulation to perturb processing by APC and suppression of the cell-mediated response to acapsular cryptococci.

MATERIALS AND METHODS

Reagents and media.RPMI 1640 medium and fetal calf serum (FCS) were obtained from Eurobio Laboratories (Paris, France). Human serum (HS) was obtained from Biosource International (Camarillo, Calif.). GXM was isolated from culture supernatant fluid of a serotype A strain (ATCC 24064) that was grown on a liquid synthetic medium (4) on a gyratory shaker for 4 days at 30°C. GXM was isolated by use of differential precipitation with ethanol and hexadecyl trimethyl ammonium bromide (CTAB; Sigma Chemical Co., St. Louis, Mo.) (3). The isolation procedure has been described in detail elsewhere (12). Lipopolysaccharide (LPS) fromEscherichia coli O55:135 was obtained from Difco Laboratories (Detroit, Mich.). Concanavalin A (ConA) and polymyxin B were purchased from Sigma. Anti-IL-10 MAb was obtained from Genzyme Corp. (Boston, Mass.). RPMI 1640, FCS, C. neoformans cells (approximately 5 × 108), ConA, anti-IL-10 MAb, and HS were tested for endotoxin contamination by a Limulusamebocyte lysate (LAL) assay (Sigma) which had a sensitivity of approximately 0.05 to 0.1 ng of E. coli LPS/ml. All reagents tested negative. The GXM was not examined by LAL because GXM preparations, even those made under stringent conditions designed to minimize or eliminate LPS contamination, routinely test positive in LAL assays, suggesting that contamination of GXM with endotoxin cannot be accurately assessed by LAL.

Preparation of peripheral blood monocytes (PBM) and lymphocytes.Heparinized venous blood, obtained from healthy donors, was diluted with RPMI 1640 plus 5% FCS (cRPMI), and the mononuclear cells were separated by density gradient centrifugation on Ficoll-Hypaque (35). The mononuclear cells were washed twice in cRPMI and incubated for 1 h at a concentration of 2 × 106 to 3 × 106/ml in cell culture petri dishes (Nunc Inter Med, Roskilde, Denmark). The remaining adherent cells (approximately 2 × 104/well) were >98% esterase positive and >98% viable as evaluated by trypan blue dye exclusion. Nonadherent cells were E rosetted as previously described (37). The cells recovered were T lymphocytes [T(E+), >98% CD3+ as evaluated by flow cytometry analysis].

Microorganisms.The two strains of C. neoformansexamined in this study were obtained from J. Orendi (Central Bureau Schimmel Cultures [CBS], Delft, The Netherlands). C. neoformans var. neoformans 6995 (CBS 6995; also known as NIH 37) is a thinly encapsulated isolate of serotype A. C. neoformans var. neoformans 7698 (CBS 7698; also known as NIH B-4131) is an acapsular mutant. Candida albicans PCA-2 was kindly supplied by D. Kerridge, Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom. This is an agerminative strain which grows as a pure yeast form in vitro at both 28 and 37°C in conventional mycological media. The morphological characteristics and conditions for growth of the two strains of C. neoformansand the C. albicans isolate have been described previously (41-43). The cultures were maintained by serial passage on Sabouraud agar (BioMerieux, Lyon, France) and harvested by suspending a single colony in RPMI 1640. The cells were washed twice, counted on a hematocytometer, and adjusted to the desired concentration. Cells ofC. neoformans 6995 and 7698 and C. albicans were killed by autoclaving.

Phagocytosis.Phagocytosis assays were performed as previously described (45). Briefly, live C. neoformans 6995 or 7698 or C. albicans cells were added to PBM monolayers cultured in RPMI 1640 plus 10% unheated HS at an effector-to-target cell ratio of 1:1. After 1 h of incubation at 37°C in 5% CO2, nonadherent microorganisms were removed by extensive washing. The percent phagocytosis was calculated as the proportion of PBM containing one or more yeast cells per 100 PBM counted.

Lymphocyte proliferation assay.Monolayers of PBM (2 × 104), adherent in flat-bottom 96-well plates, were incubated with or without heat-inactivated C. neoformans(2 × 105) for 2 h at 37°C in 5% CO2 in RPMI 1640 plus 10% HS and used throughout as APC. The PBM monolayers were washed to remove nonbound microorganisms, and autologous T(E+) cells (105) in RPMI 1640 plus 10% HS were added to the cultures. In selected experiments, ConA (5 μg/ml) was added to cocultures of PBM and T(E+) autologous lymphocytes. In selected experiments, supernatant fluids were harvested after 3 or 7 days of culture for IL-10 determination. At various days, cultures were pulsed for 6 h with 0.5 μCi of [3H]thymidine (Amersham International, Amersham, United Kingdom), and the nonadherent contents of the wells were collected onto filter paper by using a cell harvester (Flow Laboratories, McLean, Va.). The dried filters were counted directly in a β counter (Packard Instruments, Downers Grove, Ill.). In all experiments, the proliferating cell population was >98% CD3 positive as evaluated by flow cytometry analysis. Mouse anti-human CD3 (immunoglobulin G2a [IgG2a]) was obtained from Caltag Laboratories (South San Francisco, Calif.). The viability of the lymphocytes and the adherent cells after 3 and 7 days was >98% in each experimental group, as evaluated by trypan blue dye exclusion. Proliferation was expressed as mean values of thymidine uptake of the indicated number of replicates ± standard error of the mean (SEM).

Flow cytometry analysis.PBM untreated or treated with various stimuli were harvested by scraping into phosphate-buffered saline containing 0.5% bovine serum albumin and 0.4% sodium azide. A total of 106 cells in 50 μl were mixed with 10 μl of a fluorescein isothiocyanate-conjugated mouse MAb that is specific for human IgG1 (Sigma) or 10 μl of a fluorescein isothiocyanate-conjugated mouse MAb that is specific for human HLA-DR (Boehringer, Mannheim, Germany). After 45 min of incubation, the cells were washed three times and stained with phycoerythrin-conjugated anti-human CD4 (Caltag). Mouse monoclonal anti-human CD14R (IgG2b)-phycoerythrin conjugate was purchased from Ancell Corporation (Bayport, Minn.). For each sample, MHC class II expression was measured on the surface of CD14 positive cells by using a fluorescence-activated cell sorter (Becton Dickinson).

Cytokine determination.IL-10 was determined with a human IL-10 enzyme-linked immunosorbent assay (ELISA) kit purchased from Genzyme. The Predicta IL-10 kit is a solid-phase ELISA based on the antibody sandwich principle; its sensitivity is 5 pg/ml. Specificity was determined by measuring IL-10 with no detectable cross-reaction with human IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, gamma interferon, α-2-microglobulin, granulocyte-macrophage colony-stimulating factor, leukocyte inhibiting factor, stem cell factor, TNF-α, TNF-β in IL-10, and bovine serum.

Statistical analysis.Statistical analysis was performed with Student’s t test.

RESULTS

Previous reports by ourselves (42, 43) and others (5, 26) demonstrated that encapsulation of C. neoformans influences T-cell proliferation in response to C. neoformans-treated monocytes. To determine whether the GXM component of the cryptococcal capsule is responsible for the observed phenomenon, we added various amounts of GXM and acapsular cells ofC. neoformans 7698 (2 × 105) to monocytes (2 × 104) at the time of monocyte preparation. Subsequently, autologous T lymphocytes (105) were added, and lymphoproliferation was measured after 3 or 7 days of culture. The results (Table 1) showed that GXM inhibited the T-cell blastogenic response in a dose-dependent manner. To exclude the possibility that the GXM-mediated inhibition was due to contamination by LPS, we performed a similar experiment in the presence or absence of polymyxin B. The results (Table2) showed that the inhibitory effect of GXM is not attributable to LPS contamination because (i) incorporation of polymyxin B into the medium had no significant effect on the subsequent T-cell response and (ii) addition of LPS to cells of strain 7698 caused an increase in the T-cell lymphoproliferative response rather than the decreased response observed in the presence of GXM.

View this table:
  • View inline
  • View popup
Table 1.

Effect of GXM on the proliferative response of T(E+) to PBM pretreated with acapsular C. neoformans 7698

View this table:
  • View inline
  • View popup
Table 2.

Effect of polymyxin B on the T-cell proliferative response to monocytes pretreated with LPS or with acapsular C. neoformans 7698 plus GXM

Incubation of acapsular cryptococci with purified GXM leads to binding of GXM to the yeast surface (14, 16, 40) and renders the acapsular cryptococci resistant to phagocytosis (2, 14). As a consequence, we considered the possibility that the inhibitory activity of GXM is related to the ability of GXM to coat the surface of the acapsular cells. GXM (50 μg in a total volume of 0.2 ml) was mixed with cells of strain 7698 (2 × 105) for 30 min, and then the cells were washed to remove nonadherent GXM and added to APC. We also evaluated the effect of GXM on APC functions in assays using an unrelated antigen (C. albicans). APC (2 × 104) were treated with C. albicans (2 × 105) and GXM (50 μg in a total volume of 0.2 ml), and then T lymphocytes (105) were added. The results (Fig.1) showed significant (P< 0.01) and similar inhibition of T-cell proliferation regardless of whether (i) GXM was added simultaneously with the acapsular cells, (ii) acapsular cells were pretreated with GXM and washed [Fig. 1, (7698 + GXM) W] and then added to APC in the absence of free GXM, (iii) GXM was present in the form of naturally encapsulated cryptococci. In contrast, GXM had little effect on the proliferative response to C. albicans. In every instance, inhibition of proliferation was accompanied by an inhibition of phagocytosis [Fig.1, (7698 + GXM) W, 7698 + GXM, or 6995]. In contrast, treatments that elicited a strong proliferative response (Fig. 1, CA+GXM, CA, or 7698) were also characterized by high levels of phagocytosis.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Correlation between T-cell proliferative response to monocytes pretreated with the acapsular strain of C. neoformans (7698) in the absence or presence of GXM and phagocytic capability of monocytes. Percent phagocytosis was calculated as the percentage of PBM containing 1 or more yeast cells per 100 cells counted as described in Materials and Methods. GXM (250 μg/ml) was added at the time of acapsular C. neoformans 7698 orC. albicans (CA) treatment. GXM (250 μg/ml) was also preincubated with acapsular C. neoformans 7698 for 30 min at 37°C, and then the cells were washed twice to remove nonadherent GXM and added to PBM [(7698 + GXM) W]. Values represent the mean counts per minute ± SEM of three separate experiments from three different donors. For experimental details, see Table 1. ∗,P < 0.001 (GXM-treated versus untreated cells). NS, not stimulated.

IL-10 has been found to completely prevent antigen-specific T-cell proliferation by inhibiting monocyte antigen-presenting capacity (6, 7). As a consequence, we examined IL-10 production during coculture of C. neoformans-treated monocytes with T lymphocytes under the same conditions as used in the experiment described above. Small samples were collected on days 3 and 7, and IL-10 concentrations were determined. The results (Table3) showed that IL-10 production after coculture with strain 7698 was only slightly greater than levels observed in the absence of the cryptococcal cells. In contrast, coculture in the presence of encapsulated cryptococci (strain 6995) resulted in a significant (P = 0.008) elevation in extracellular IL-10 levels. Peak levels of IL-10 were observed after 3 days incubation, with a slight decrease in IL-10 levels occurring at 7 days.

View this table:
  • View inline
  • View popup
Table 3.

IL-10 levels in supernatant fluids of cocultures of T lymphocytes plus C. neoformans-treated monocytes

IL-10 secreted in response to encapsulated C. neoformansrepresents an inhibitory factor that could, in part, explain the downregulation of T-cell proliferation. As a consequence, we evaluated the effect of addition of anti-IL-10 MAbs on the proliferative response to encapsulated (strain 6995) or nonencapsulated (strain 7698) cryptococci. The results (Table 4) showed that addition of anti-IL-10 upregulated (P < 0.01) lymphoproliferation induced by the encapsulated strain (6995) but had no significant effect (P > 0.05) on the proliferative response to nonencapsulated C. neoformans. An alternative explanation for upregulation by the anti-IL-10 MAb is the presence of LPS contamination of MAb preparation. A role for contaminating LPS was excluded by LAL assay and by a parallel experiment in which polymyxin B (50 μg/ml) was added at the time of coculture. The results were unchanged in the presence of polymyxin B (data not shown). Additionally, a role for LPS contamination of the MAb preparation in upregulation of the proliferative response to encapsulated cryptococci is unlikely because the anti-IL-10 MAb had no effect on the proliferative response to acapsular cryptococci (strain 7698).

View this table:
  • View inline
  • View popup
Table 4.

Effect of the addition of anti-IL-10 MAb on proliferative response of T lymphocytes to C. neoformans-treated monocytes

Previous studies by de Waal Malefyt found that IL-10 reduces antigen-specific T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via a downregulation of class II MHC molecules (6, 7). Our recent results show that exogenous IL-10 regulates APC function of monocytes exposed to C. neoformans (27). The observation that endogenous IL-10 downregulates the proliferative response to encapsulated cryptococci (Table 4) suggested a paracrine role for endogenous IL-10 in reducing antigen-specific T-cell proliferation by diminishing the accessory function of monocytes via downregulation of MHC class II molecule expression. Thus, we analyzed class II MHC molecular expression in monocytes treated with acapsular C. neoformans 7698 in the presence or absence of various amounts of GXM, as well as after challenge with encapsulated strain 6995 in the absence or presence of MAb anti-IL-10. The results (Fig. 2) show that acapsular strain 7698 upregulates constitutive HLA-DR expression on monocytes. The addition of GXM inhibits, in a dose-dependent fashion, HLA-DR expression induced by treatment with strain 7698. Moreover, the absence of increased HLA-DR expression observed when monocytes were stimulated with encapsulated cryptococci was reversed by incorporation of an anti-IL-10 MAb into the incubation mixture. These results indicate a role for GXM and encapsulation in inhibiting expression of MHC class II molecules on monocytes, via an IL-10-dependent process.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

HLA-DR molecule expression on monocytes untreated (None) or treated with the acapsular strain of C. neoformans (7698) in the absence or presence of various concentrations of GXM or treated with the encapsulated strain of C. neoformans (6995) in the absence or presence of anti-IL-10 MAb. Monocytes were cultured for 24 h and analyzed for HLA-DR expression. The results are the mean fluorescence intensity ± SEM of three experiments performed. The mean fluorescence intensity of monocytes treated with isotype-matched MAb was 8 ± 2. ∗, P < 0.05 (Cryptococcus-treated versus untreated cells).

DISCUSSION

Results from this study show that T lymphocytes proliferate in response to incubation with APC that have been pretreated with acapsular cryptococci. In contrast, APC pretreated with encapsulated cryptococci have little or no ability to stimulate T-cell proliferation. Thus, the presence of a capsule is associated with decreased lymphoproliferation. The cryptococcal capsule is undoubtedly comprised of several constituents. The observation that acapsular cryptococci can be incubated with purified GXM and washed and acquire a diminished ability to stimulate lymphoproliferation (Table 1) identifies GXM as the capsular component which mediates the suppression. These results confirm similar observations by ourselves (39, 40, 43) and others (5, 26). A role for GXM in the suppressive phenomenon is further supported by our more recent study which found that anti-GXM MAbs are able to upregulate APC function of monocytes treated with encapsulated cryptococci (44). Effects of MAb treatment of encapsulated cryptococci included enhancement of T-cell lymphoproliferative response and a reduction of endogenous IL-10 production.

Our studies provide new insight into the mechanisms for capsule-mediated suppression of T lymphoproliferation by identifying a role for endogenous IL-10 in the suppressive phenomenon and correlating GXM-dependent reduced APC function with downregulation of HLA-DR expression on monocytes. Coculture of encapsulated cryptococci with monocytes and T lymphocytes led to elevated levels of IL-10 in culture supernatant fluids. We have previously reported that supernatant fluids of monocytes cultured with encapsulated cryptococci have higher levels of IL-10 than supernatant fluids of monocytes cultured with acapsular cryptococci (46). The present study directly links the increased levels of IL-10 with GXM-dependent suppressed T lymphoproliferation because addition of anti-IL-10 MAbs to the culture medium reversed the suppression.

Previous studies found that IL-10 reduces antigen-specific proliferation of human T cells by reducing the antigen-presenting capacity of monocytes via downregulation of class II MHC expression (7). Given our observation that IL-10 plays a critical role in suppression of the lymphoproliferative response to C. neoformans antigens (27), we assessed the effect of GXM encapsulation on expression of HLA-DR on monocytes. The finding that expression of HLA-DR is suppressed on monocytes exposed to encapsulated cryptococci or GXM-treated acapsular cryptococci is consistent with our recent observations that establish a clear link between IL-10-induced downregulation of class II MHC expression on monocytes exposed toC. neoformans (27). The present results confirm and extend our previous data (27) indicating an autocrine/paracrine role for endogenous IL-10 in dampening APC capacity of monocytes, with consequent reduction of T-cell response.

Our conclusions regarding the effects of encapsulation on the antigen-presenting capacity of monocytes are based on comparisons of encapsulated and acapsular cryptococci as well as the effect of experimental GXM encapsulation of acapsular cryptococci. Several possible caveats should be noted. First, the encapsulated and acapsular isolates are not isogenic; therefore, we cannot rule out a phenotypic difference that accounts for the observed results. However, the similarity in the effect of GXM-treated acapsular cryptococci and the effect of encapsulated cryptococci argues for a GXM-biased response. Second, the possibility of LPS contamination of the GXM preparation must be considered. It is unlikely that LPS contamination accounts for inhibition of the T-cell lymphoproliferative response because (i) inhibition was also observed with encapsulated cryptococci that were not subjected to the prolonged processing inherent in purification of GXM, (ii) inhibition was observed with acapsular cryptococci that were treated with GXM and washed to remove nonadherent polysaccharide, (iii) GXM did not suppress the T-cell proliferative response to C. albicans, (iv) inhibition was not blocked by incorporation of polymyxin B into the medium, and (v) the T-cell proliferative response to acapsular cryptococci was enhanced (rather than inhibited) by incorporation of LPS into the incubation medium. Finally, there is the possibility that suppression of the T-cell proliferative response is due to contamination of GXM by CTAB used for isolation of GXM. It is unlikely that CTAB accounts for the observed suppression because (i) similar levels of suppression were observed with encapsulated cryptococci that were not treated with CTAB and (ii) GXM did not suppress the T-cell proliferative response to C. albicans.

The mechanism by which encapsulation with GXM mediates suppression of the T lymphoproliferative response remains to be determined. GXM binds to the surface of acapsular cryptococci, leading to inhibition of phagocytosis (14, 15). The observation that decreased T lymphoproliferation paralleled decreased phagocytosis (Fig. 1) suggests that suppression might be due to nothing more than an inability to be ingested. Such inhibition of phagocytosis could reduce processing by APC and subsequent stimulation of T-cell proliferation. This passive role by GXM encapsulation is not consistent with the observation that coincubation of monocytes and T lymphocytes with encapsulated cryptococci leads to increased levels of IL-10 in the culture supernatant fluids. Moreover, addition of anti-IL-10 MAbs to the incubation mixture restored the T lymphoproliferative response to encapsulated cryptococci to levels observed with acapsular cryptococci. This finding suggests that GXM encapsulation plays an active role in suppression of APC-dependent lymphoproliferation.

There are at least two mechanisms by which GXM encapsulation could actively modulate the lymphoproliferative response. First, GXM could directly bind to monocytes, leading to release of IL-10. In support of this mechanism, Blackstock reported that APC treated with GXM can be washed and still retain the ability to induce release of a T-suppressor factor from an inducible T-T hybridoma (1). Also in agreement with a direct stimulation of monocytes by GXM, Dong and Murphy have reported evidence that GXM binds CD18 on human neutrophils (9). An alternative mechanism for an active role in stimulation of monocytes is the possibility that GXM encapsulation leads to enhanced activation of the complement system. The cryptococcal capsule is a powerful activator of the complement system (18, 20). Complement cleavage fragments such as C3a or C5a could stimulate monocytes, with a consequent release of IL-10. Studies in progress in our laboratories are examining both the direct interaction between GXM and monocytes and the role of complement cleavage fragments in GXM-dependent modulation of monocyte function.

ACKNOWLEDGMENTS

We are grateful to Eileen Mahoney Zannetti for excellent technical assistance.

This study was supported by IX Progetto AIDS (contract 9404-39), Italy, and by Public Health Service grant AI-14209 (to T.R.K.).

FOOTNOTES

    • Received 18 September 1997.
    • Returned for modification 21 October 1997.
    • Accepted 21 November 1997.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Blackstock R.
    Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34 1996 19 30
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Bulmer G. S.,
    2. Sans M. D.
    Cryptococcus neoformans. III. Inhibition of phagocytosis. J. Bacteriol. 95 1968 5 8
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Cherniak R.,
    2. Reiss E.,
    3. Slodki M. E.,
    4. Plattner R. D.,
    5. Blumer S. O.
    Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans. Mol. Immunol. 17 1980 1025 1032
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Cherniak R.,
    2. Reiss E.,
    3. Turner S. H.
    A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103 1982 239 250
    OpenUrlCrossRef
  5. 5.↵
    1. Collins H. L.,
    2. Bancroft G. I.
    Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect. Immun. 59 1991 3883 3888
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. de Waal Malefyt R.,
    2. Abrams J.,
    3. Bennett B.,
    4. Figdor C. G.,
    5. de Vries J. E.
    Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174 1991 1209 1220
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. de Waal Malefyt R.,
    2. Haanen J.,
    3. Spits H.,
    4. Roncarolo M. G.,
    5. Te Velde A.,
    6. Figdor C.,
    7. Johnson K.,
    8. Kastelein R.,
    9. Yssel H.,
    10. de Vries J. E.
    Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174 1991 915 924
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Diamond R. D.,
    2. Bennett J. E.
    Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann. Intern. Med. 80 1974 176 181
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Dong Z. M.,
    2. Murphy J. W.
    Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect. Immun. 65 1997 557 563
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Eng R. H. K.,
    2. Bishburg E.,
    3. Smith S. M.,
    4. Kapila R.
    Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81 1986 19 23
    OpenUrlPubMedWeb of Science
  11. 11.↵
    1. Good C. B.,
    2. Coax W. A.
    Cryptococcal infections in patients with AIDS. N. Engl. J. Med. 322 1990 701 702
    OpenUrlPubMed
  12. 12.↵
    1. Houpt D. C.,
    2. Pfrommer G. S. T.,
    3. Young B. J.,
    4. Larson T. A.,
    5. Kozel T. R.
    Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62 1994 2857 2864
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Khakpour F. R.,
    2. Murphy J. W.
    Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect. Immun. 55 1987 1657 1662
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Kozel T. R.
    Nonencapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect. Immun. 16 1977 99 106
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kozel T. R.,
    2. Gotschlich E. C.
    The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast macrophages. J. Immunol. 129 1982 1675 1680
    OpenUrlAbstract
  16. 16.↵
    1. Kozel T. R.,
    2. Hermerath C. A.
    Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect. Immun. 43 1984 879 886
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kozel T. R.,
    2. Mastroianni R. P.
    Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14 1976 62 67
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kozel T. R.,
    2. Pfrommer G. S. T.
    Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52 1986 1 5
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kozel T. R.,
    2. Pfrommer G. S. T.,
    3. Redelman D.
    Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clin. Exp. Immunol. 70 1987 238 246
    OpenUrlPubMed
  20. 20.↵
    1. Kozel T. R.,
    2. Wilson M. A.,
    3. Pfrommer G. S. T.,
    4. Schlageter A. M.
    Activation and binding of opsonic fragments of C3 onto encapsulated Cryptococcus neoformans using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57 1989 1922 1927
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Levitz S. M.,
    2. Tabuni A.,
    3. Kornfield H.,
    4. Reardon C. C.,
    5. Golenbock D. T.
    Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect. Immun. 62 1994 1975 1981
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Levitz S. M.,
    2. Tabuni A.,
    3. Nang S.-H.,
    4. Golenbock D. T.
    Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans,Candida albicans, and lipopolysaccharide. Infect. Immun. 64 1996 945 951
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Miller G. P. G.,
    2. Kohl S.
    Antibody-dependent leukocyte killing of Cryptococcus neoformans. J. Immunol. 131 1983 1455 1459
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Miller M. F.,
    2. Mitchell T. G.
    Killing of Cryptococcus neoformans strain by human neutrophils and monocytes. Infect. Immun. 59 1991 24 28
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Mitchell T. G.,
    2. Perfect J. R.
    Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8 1995 515 548
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Mody C. H.,
    2. Syme R. M.
    Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect. Immun. 61 1993 464 468
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Monari C.,
    2. Retini C.,
    3. Palazzetti B.,
    4. Bistoni F.,
    5. Vecchiarelli A.
    Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin. Exp. Immunol. 109 1997 242 248
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Mukherjee S.,
    2. Lee S. C.,
    3. Casadevall A.
    Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63 1995 573 579
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Murphy J. W.
    Effects of first-order Cryptococcus-specific suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect. Immun. 48 1985 439 445
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Murphy J. W.,
    2. Cox R. A.
    Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen. Clin. Exp. Immunol. 73 1988 174 180
    OpenUrlPubMedWeb of Science
  31. 31.↵
    1. Murphy J. W.,
    2. Cozad G. C.
    Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5 1972 896 901
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Murphy J. W.,
    2. Moorhead J. W.
    Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J. Immunol. 128 1982 276 282
    OpenUrlAbstract
  33. 33.↵
    1. Murphy J. W.,
    2. Mosley R. L.
    Regulation of cell-mediated immunity to cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J. Immunol. 134 1985 577 584
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Murphy J. W.,
    2. Mosley R. L.,
    3. Moorhead J. W.
    Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells and induction of second-order suppressor cells. J. Immunol. 130 1983 2876 2881
    OpenUrlAbstract
  35. 35.↵
    1. Orendi J. M.,
    2. Nottet H. S. L. M.,
    3. Visser M. R.,
    4. Verheul A. F. M.,
    5. Snippe H.,
    6. Verhoef J.
    Enhancement of HIV-1 replication in peripheral blood mononuclear cells by Cryptococcus neoformans is monocyte-dependent but tumor necrosis factor-independent. AIDS 8 1994 423 429
    OpenUrlPubMedWeb of Science
  36. 36.↵
    1. Pettoello-Mantovani M.,
    2. Casadevall A.,
    3. Smarnoworawong P.,
    4. Goldstein H.
    Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae AIDS Res. Hum. Retroviruses 10 1994 1079 1084
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Pfeffer K.,
    2. Shoel B.,
    3. Gies H.,
    4. Kaufmann S. H. E.,
    5. Wagner H.
    Primary responses of human mycobacteria: a frequent set of γ/δ T cells are stimulated by protease-resistant ligands. Eur. J. Immunol. 20 1990 1175 1179
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Powderly, W. G. 1992. Therapy for cryptococcal meningitis in patients with AIDS Clin. Infect. Dis.14(Suppl. 1):S54–S59.
  39. 39.↵
    1. Retini C.,
    2. Vecchiarelli A.,
    3. Monari C.,
    4. Tascini C.,
    5. Bistoni F.,
    6. Kozel T. R.
    Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64 1996 2897 2903
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Small J. M.,
    2. Mitchell T. G.
    Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants. Infect. Immun. 54 1986 742 750
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Vecchiarelli A.,
    2. Dottorini M.,
    3. Beccari T.,
    4. Cociani C.,
    5. Todisco T.,
    6. Bistoni F.
    Inhibition of candidacidal activity of polymorphonuclear cells by alveolar macrophage-derived factor from lung cancer patients. Am. Rev. Respir. Dis. 147 1993 414 419
    OpenUrlPubMedWeb of Science
  42. 42.↵
    1. Vecchiarelli A.,
    2. Dottorini M.,
    3. Pietrella D.,
    4. Monari C.,
    5. Retini C.,
    6. Todisco T.,
    7. Bistoni F.
    Role of alveolar macrophages as antigen presenting cells in Cryptococcus neoformans infection. Am. J. Respir. Cell Mol. Biol. 11 1994 130 137
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Vecchiarelli A.,
    2. Pietrella D.,
    3. Dottorini M.,
    4. Monari C.,
    5. Retini C.,
    6. Todisco T.,
    7. Bistoni F.
    Encapsulation of Cryptococcus neoformans regulates fungicidal activity and antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98 1994 217 223
    OpenUrlPubMedWeb of Science
  44. 44.↵
    1. Vecchiarelli A.,
    2. Retini C.,
    3. Casadevall A.,
    4. Bistoni F.
    Monoclonal antibody to Cryptococcus neoformans glucuronoxylomannan enhances antigen presenting capacity of human monocytes, abstr. 2.4 Third International Conference on Cryptococcus & Cryptococcosis. Paris, France 1996 172
  45. 45.↵
    1. Vecchiarelli A.,
    2. Retini C.,
    3. Pietrella D.,
    4. Monari C.,
    5. Tascini C.,
    6. Beccari T.,
    7. Kozel T. R.
    Downregulation of cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect. Immun. 63 1995 2919 2923
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Vecchiarelli A.,
    2. Retini C.,
    3. Monari C.,
    4. Tascini C.,
    5. Bistoni F.,
    6. Kozel T. R.
    Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64 1996 2846 2849
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes
Cinzia Retini, Anna Vecchiarelli, Claudia Monari, Francesco Bistoni, Thomas R. Kozel
Infection and Immunity Feb 1998, 66 (2) 664-669; DOI: 10.1128/IAI.66.2.664-669.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes
Cinzia Retini, Anna Vecchiarelli, Claudia Monari, Francesco Bistoni, Thomas R. Kozel
Infection and Immunity Feb 1998, 66 (2) 664-669; DOI: 10.1128/IAI.66.2.664-669.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antigen presentation
Cryptococcus neoformans
monocytes
polysaccharides

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522